Treatment Resistant Depression Market Report

Global and Region Treatment Resistant Depression Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 01, 2022
  • PAGES：199
  • REPORT CODE：GMM974358
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Treatment Resistant Depression market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Treatment Resistant Depressionmarket, defines the market attractiveness level of Treatment Resistant Depression market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Treatment Resistant Depression industry, describes the types of Treatment Resistant Depression market, the applications of major players and the market size, and deeply analyzes the current situation of the global Treatment Resistant Depression market and the development prospects and opportunities of Treatment Resistant Depression industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Treatment Resistant Depression market in Chapter 13.

    By Player:

    • Allergan/Gedeon Richter's

    • COMPASS Pathways

    • Johnson & Johnson/Minerva Neurosciences

    • Relmada Therapeutics

    • Eli Lilly and Company

    • Johnson & Johnson

    • COMPASS Pathways/Minerva Neurosciences

    • Celon Pharma

    • VistaGen Therapeutics

    • ACADIA Pharmaceuticals

    • Axsome Therapeutics

    • Allergan

    • Novartis

    By Type:

    • Selective Serotonin Reuptake Inhibitors

    • Monoamine Oxidase Inhibitors

    • Tricyclic Antidepressant

    • Esketamine Nasal Spray

    By End-User:

    • Hospitals

    • Clinics

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Treatment Resistant Depression Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Treatment Resistant Depression Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Treatment Resistant Depression Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Treatment Resistant Depression Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Treatment Resistant Depression Market Analysis and Outlook to 2022

    • 7.1 Global Treatment Resistant Depression Consumption (2017-2022)

    • 7.2 United States Treatment Resistant Depression Consumption (2017-2022)

    • 7.3 Europe Treatment Resistant Depression Consumption (2017-2022)

    • 7.4 China Treatment Resistant Depression Consumption (2017-2022)

    • 7.5 Japan Treatment Resistant Depression Consumption (2017-2022)

    • 7.6 India Treatment Resistant Depression Consumption (2017-2022)

    • 7.7 South Korea Treatment Resistant Depression Consumption (2017-2022)

    8 Region and Country-wise Treatment Resistant Depression Market Analysis and Outlook to 2028

    • 8.1 Global Treatment Resistant Depression Consumption Forecast (2022-2028)

    • 8.2 United States Treatment Resistant Depression Consumption Forecast (2022-2028)

    • 8.3 Europe Treatment Resistant Depression Consumption Forecast (2022-2028)

    • 8.4 China Treatment Resistant Depression Consumption Forecast (2022-2028)

    • 8.5 Japan Treatment Resistant Depression Consumption Forecast (2022-2028)

    • 8.6 India Treatment Resistant Depression Consumption Forecast (2022-2028)

    • 8.7 South Korea Treatment Resistant Depression Consumption Forecast (2022-2028)

    9 Global Treatment Resistant Depression Market Outlook by Types and Applications to 2022

    • 9.1 Global Treatment Resistant Depression Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Selective Serotonin Reuptake Inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Monoamine Oxidase Inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Tricyclic Antidepressant Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Esketamine Nasal Spray Consumption and Growth Rate (2017-2022)

    • 9.2 Global Treatment Resistant Depression Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Global Treatment Resistant Depression Market Outlook by Types and Applications to 2028

    • 10.1 Global Treatment Resistant Depression Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Selective Serotonin Reuptake Inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Monoamine Oxidase Inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Tricyclic Antidepressant Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Esketamine Nasal Spray Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Treatment Resistant Depression Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global Treatment Resistant Depression Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Treatment Resistant Depression Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Treatment Resistant Depression Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Treatment Resistant Depression Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Treatment Resistant Depression Market Competitive Analysis

    • 14.1 Allergan/Gedeon Richter's

      • 14.1.1 Allergan/Gedeon Richter's Company Details

      • 14.1.2 Allergan/Gedeon Richter's Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Allergan/Gedeon Richter's Treatment Resistant Depression Product and Service

    • 14.2 COMPASS Pathways

      • 14.2.1 COMPASS Pathways Company Details

      • 14.2.2 COMPASS Pathways Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 COMPASS Pathways Treatment Resistant Depression Product and Service

    • 14.3 Johnson & Johnson/Minerva Neurosciences

      • 14.3.1 Johnson & Johnson/Minerva Neurosciences Company Details

      • 14.3.2 Johnson & Johnson/Minerva Neurosciences Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Johnson & Johnson/Minerva Neurosciences Treatment Resistant Depression Product and Service

    • 14.4 Relmada Therapeutics

      • 14.4.1 Relmada Therapeutics Company Details

      • 14.4.2 Relmada Therapeutics Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Relmada Therapeutics Treatment Resistant Depression Product and Service

    • 14.5 Eli Lilly and Company

      • 14.5.1 Eli Lilly and Company Company Details

      • 14.5.2 Eli Lilly and Company Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Eli Lilly and Company Treatment Resistant Depression Product and Service

    • 14.6 Johnson & Johnson

      • 14.6.1 Johnson & Johnson Company Details

      • 14.6.2 Johnson & Johnson Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Johnson & Johnson Treatment Resistant Depression Product and Service

    • 14.7 COMPASS Pathways/Minerva Neurosciences

      • 14.7.1 COMPASS Pathways/Minerva Neurosciences Company Details

      • 14.7.2 COMPASS Pathways/Minerva Neurosciences Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 COMPASS Pathways/Minerva Neurosciences Treatment Resistant Depression Product and Service

    • 14.8 Celon Pharma

      • 14.8.1 Celon Pharma Company Details

      • 14.8.2 Celon Pharma Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Celon Pharma Treatment Resistant Depression Product and Service

    • 14.9 VistaGen Therapeutics

      • 14.9.1 VistaGen Therapeutics Company Details

      • 14.9.2 VistaGen Therapeutics Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 VistaGen Therapeutics Treatment Resistant Depression Product and Service

    • 14.10 ACADIA Pharmaceuticals

      • 14.10.1 ACADIA Pharmaceuticals Company Details

      • 14.10.2 ACADIA Pharmaceuticals Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 ACADIA Pharmaceuticals Treatment Resistant Depression Product and Service

    • 14.11 Axsome Therapeutics

      • 14.11.1 Axsome Therapeutics Company Details

      • 14.11.2 Axsome Therapeutics Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Axsome Therapeutics Treatment Resistant Depression Product and Service

    • 14.12 Allergan

      • 14.12.1 Allergan Company Details

      • 14.12.2 Allergan Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Allergan Treatment Resistant Depression Product and Service

    • 14.13 Novartis

      • 14.13.1 Novartis Company Details

      • 14.13.2 Novartis Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 Novartis Treatment Resistant Depression Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Treatment Resistant Depression

    • Figure Treatment Resistant Depression Picture

    • Table Global Treatment Resistant Depression Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Treatment Resistant Depression Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Treatment Resistant Depression Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Treatment Resistant Depression Consumption by Country (2017-2022)

    • Figure United States Treatment Resistant Depression Consumption and Growth Rate (2017-2022)

    • Table Europe Treatment Resistant Depression Consumption and Growth Rate (2017-2022)

    • Figure China Treatment Resistant Depression Consumption and Growth Rate (2017-2022)

    • Figure Japan Treatment Resistant Depression Consumption and Growth Rate (2017-2022)

    • Figure India Treatment Resistant Depression Consumption and Growth Rate (2017-2022)

    • Figure South Korea Treatment Resistant Depression Consumption and Growth Rate (2017-2022)

    • Figure Global Treatment Resistant Depression Consumption Forecast by Country (2022-2028)

    • Figure United States Treatment Resistant Depression Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Treatment Resistant Depression Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Treatment Resistant Depression Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Treatment Resistant Depression Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Treatment Resistant Depression Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Treatment Resistant Depression Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Selective Serotonin Reuptake Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Monoamine Oxidase Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Tricyclic Antidepressant Consumption and Growth Rate (2017-2022)

    • Figure Global Esketamine Nasal Spray Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals Consumption and Growth Rate (2017-2022)

    • Figure Global Clinics Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Selective Serotonin Reuptake Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Monoamine Oxidase Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Tricyclic Antidepressant Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Esketamine Nasal Spray Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Treatment Resistant Depression Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Treatment Resistant Depression Export by Region (Top 5 Countries) (2017-2028)

    • Table Allergan/Gedeon Richter's (Foundation Year, Company Profile and etc.)

    • Table Allergan/Gedeon Richter's Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

    • Table Allergan/Gedeon Richter's Treatment Resistant Depression Product and Service

    • Table COMPASS Pathways (Foundation Year, Company Profile and etc.)

    • Table COMPASS Pathways Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

    • Table COMPASS Pathways Treatment Resistant Depression Product and Service

    • Table Johnson & Johnson/Minerva Neurosciences (Foundation Year, Company Profile and etc.)

    • Table Johnson & Johnson/Minerva Neurosciences Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

    • Table Johnson & Johnson/Minerva Neurosciences Treatment Resistant Depression Product and Service

    • Table Relmada Therapeutics (Foundation Year, Company Profile and etc.)

    • Table Relmada Therapeutics Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

    • Table Relmada Therapeutics Treatment Resistant Depression Product and Service

    • Table Eli Lilly and Company (Foundation Year, Company Profile and etc.)

    • Table Eli Lilly and Company Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eli Lilly and Company Treatment Resistant Depression Product and Service

    • Table Johnson & Johnson (Foundation Year, Company Profile and etc.)

    • Table Johnson & Johnson Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

    • Table Johnson & Johnson Treatment Resistant Depression Product and Service

    • Table COMPASS Pathways/Minerva Neurosciences (Foundation Year, Company Profile and etc.)

    • Table COMPASS Pathways/Minerva Neurosciences Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

    • Table COMPASS Pathways/Minerva Neurosciences Treatment Resistant Depression Product and Service

    • Table Celon Pharma (Foundation Year, Company Profile and etc.)

    • Table Celon Pharma Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celon Pharma Treatment Resistant Depression Product and Service

    • Table VistaGen Therapeutics (Foundation Year, Company Profile and etc.)

    • Table VistaGen Therapeutics Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

    • Table VistaGen Therapeutics Treatment Resistant Depression Product and Service

    • Table ACADIA Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table ACADIA Pharmaceuticals Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

    • Table ACADIA Pharmaceuticals Treatment Resistant Depression Product and Service

    • Table Axsome Therapeutics (Foundation Year, Company Profile and etc.)

    • Table Axsome Therapeutics Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

    • Table Axsome Therapeutics Treatment Resistant Depression Product and Service

    • Table Allergan (Foundation Year, Company Profile and etc.)

    • Table Allergan Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

    • Table Allergan Treatment Resistant Depression Product and Service

    • Table Novartis (Foundation Year, Company Profile and etc.)

    • Table Novartis Treatment Resistant Depression Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis Treatment Resistant Depression Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US